Hims Hair (Finasteride + Minoxidil)vsVegamour GRO Hair Serum
Hims Hair (Finasteride + Minoxidil)
Finasteride 1mg + Minoxidil 5%
Vegamour GRO Hair Serum
Side-by-side
| # | Product | Active ingredient | Starting price | FDA status | Score | Actions |
|---|---|---|---|---|---|---|
| 1 | Hims Hair (Finasteride + Minoxidil) | Finasteride 1mg + Minoxidil 5% | Best ·$37/mo | approved | Top ·8.3 | See offer → |
| 2 | Vegamour GRO Hair Serum | — | $64/mo | supplement | 7.8 | See offer → |
Side-by-side scoring breakdown
How they work
Hims Hair targets male-pattern baldness two ways at once. Finasteride blocks the enzyme 5-alpha-reductase, which converts testosterone into DHT, the hormone that shrinks genetically susceptible scalp follicles; lowering scalp DHT slows that miniaturization. Minoxidil works on a different pathway, widening blood vessels and prolonging the follicle's active growth (anagen) phase to reactivate dormant follicles and thicken existing hairs. Used together as a daily scalp spray, they aim to slow loss (finasteride) while stimulating regrowth (minoxidil).
GRO Hair Serum is a leave-in scalp tonic that works on the hair you still have rather than acting like a drug. Its plant actives are meant to support the follicle's growth (anagen) phase and a healthier scalp. Red clover and mung bean sprout extract supply isoflavones such as biochanin A, which in laboratory studies inhibit 5-alpha-reductase, the enzyme that converts testosterone to DHT (the hormone that miniaturizes follicles in pattern hair loss). Caffeine and turmeric-derived (curcumin) callus media are intended to support the scalp environment and reduce oxidative stress, while engineered Nicotiana benthamiana peptides (marketed as plant-derived signaling peptides or "exosomes") are meant to nudge follicles toward a more favorable state. Importantly, these mechanisms are demonstrated in lab and cell or animal models of individual ingredients, not in human trials of this finished serum. The intended effect is cosmetic: hair can look thicker and shed less, but the product does not claim to chemically force regrowth the way minoxidil or finasteride do.
Effectiveness
The active ingredients are individually well-validated. In the pivotal oral finasteride 1mg trials cited on the Propecia FDA label, 48% of men had increased hair count at 12 months versus 7% on placebo; in 5-year data, 48% showed increased growth, 42% had no further loss, and about 10% continued losing. For topical minoxidil, a 393-man, 48-week randomized trial found 5% minoxidil produced roughly 45% more regrowth than 2% minoxidil by target-area hair counts. Combining a 5-alpha-reductase inhibitor with minoxidil generally outperforms either alone. Important caveat: Hims' specific compounded 0.3% topical finasteride / 6% minoxidil spray has not been studied in large dedicated FDA trials, so its exact regrowth numbers are inferred from the individual drugs, not proven for this product.
The most-cited numbers come from Vegamour's own 120-day study of 40 participants using GRO Hair Serum once daily, described by the company as independent and third-party-conducted: up to 90% reduction in visible signs of shedding and up to a 56% increase in the appearance of hair density. These are company-sponsored, "appearance"-based cosmetic outcomes, not independently published, peer-reviewed regrowth data, and "up to" reflects best-case responders rather than the average. Independent support exists only at the ingredient level: a 2025 study in mice found that transferosome-delivered red clover extract and caffeine increased the proportion of follicles in the growth phase, with effects the authors called "comparable" to 2% minoxidil, but that tested the raw actives in a delivery vehicle, not this specific formula or human scalps. By contrast, FDA-approved minoxidil has independently published, controlled human-trial evidence, with meta-analyses reporting total hair-density gains on the order of roughly 7% to 15% (somewhat higher for oral than topical) and the 5% strength outperforming 2%. Real-world reviewers often report less shedding and somewhat fuller-looking hair after about three months, though many also change other hair habits at the same time, making results hard to attribute to the serum alone.
Side effects
Local effects are most common: scalp itching, dryness, flaking, redness, or irritation from the alcohol/minoxidil base, plus possible unwanted facial hair if the product migrates. Minoxidil can cause a temporary early shed in the first weeks. Finasteride's known risks include decreased libido, erectile dysfunction, and ejaculation disorders (roughly 1-2% in oral trials, modestly above placebo). Serious or rarer concerns on the FDA finasteride label include depression, suicidal ideation, gynecomastia, and sexual side effects that can persist after stopping (sometimes called post-finasteride syndrome). Critically, in April 2025 the FDA alerted clinicians and consumers about compounded topical finasteride after reports of erectile dysfunction, anxiety, suicidal ideation, brain fog, depression, fatigue, insomnia, decreased libido, and testicular pain, many of which continued after discontinuation; topical use lowers but does not eliminate systemic absorption. Minoxidil can rarely cause dizziness or rapid heartbeat. Stop and seek care for chest pain, swelling, fainting, or mood changes.
GRO is generally well tolerated and drug-free, so it avoids minoxidil's classic side effects (unwanted facial hair, an initial shedding phase, and rare blood-pressure-related concerns). The most common issues are mild and temporary: scalp tingling, slight redness, dryness, or a faintly oily feel as the scalp adjusts in the first few weeks. Less commonly, users report allergic-type reactions such as itching, swelling, or irritation, usually tied to a botanical or fragrance ingredient (the formula contains expressed bergamot peel oil and fragrance components such as limonene and linalool). Expressed bergamot peel oil can be phototoxic, so applying at night and limiting scalp sun exposure reduces any sun-sensitivity risk. Stop use and consult a clinician if you develop a persistent rash, significant irritation, or increased shedding. Patch-test first if you have sensitive or reactive skin.
Cost & value
As of 2026, the Hims topical finasteride + minoxidil spray starts around $35/month, with the lowest per-month price when billed and shipped on a longer (for example, multi-month) cycle. For comparison, Hims oral finasteride runs about $22/month and standalone minoxidil about $15/month. There may also be a low-cost or one-time medical consultation fee. These are cash-pay telehealth/compounded products, so insurance typically does not cover them; generic oral finasteride filled at a pharmacy with a prescription can sometimes be cheaper (often around $10-25/month with discount cards) for those who do not need the topical convenience.
As of 2026, a single 1 fl oz (30 mL) bottle, about a 30-day supply, runs roughly $64 at full retail (Vegamour.com, Sephora, Amazon). Multi-month bundles and the auto-ship subscription cut the effective price to roughly $39-$49 per month (often advertised as 20-47% off), and promotional sales appear frequently. Because it is a cosmetic, it is not covered by insurance, HSA/FSA eligibility is not guaranteed, and you must keep buying it indefinitely to maintain results, so plan on roughly $470-$770+ per year. For comparison, generic FDA-approved 5% minoxidil typically costs only about $10-$15 per month, which is worth weighing if budget is a priority.
Who it's for
Designed for adult men (typically 18+) with mild-to-moderate male-pattern hair loss, especially at the crown/vertex and frontal areas; earlier treatment generally protects more hair. It requires a telehealth medical evaluation before a clinician decides whether to prescribe it. Finasteride is not approved for and should not be used by women, and it must never be handled by anyone who is or may become pregnant because of the risk of birth defects in a male fetus. Avoid if you have a finasteride or minoxidil allergy; men planning to conceive, with a history of depression, or with liver or cardiovascular concerns should discuss the risks with a clinician first.
Best for adults with early, mild, or diffuse thinning, postpartum shedding, or anyone wanting a vegan, hormone-free, drug-free way to improve the look and fullness of existing hair. It is not designed for advanced baldness or fully bare scalp areas, where no topical cosmetic can grow new follicles. Avoid or check with a clinician first if you are pregnant or breastfeeding (the serum contains expressed bergamot peel oil and biologically active plant isoflavones), have a known allergy to any listed botanical or fragrance, or have an irritated or broken scalp. Because expressed bergamot oil can be phototoxic, applying at night and protecting the scalp from sun is a sensible precaution. People with moderate-to-severe, patchy, or rapidly progressing loss should see a dermatologist for diagnosis and to discuss FDA-approved minoxidil or finasteride rather than relying on a cosmetic serum.
Bottom line
Vegamour GRO Hair Serum: Vegamour GRO Hair Serum is a plant-based cosmetic scalp serum, not an FDA-approved drug. The company's own 120-day study of 40 people claims up to 90% less shedding and a 56% increase in the appearance of density, but no independent peer-reviewed human trials confirm it regrows hair. It is best viewed as a cosmetic boost for early, mild thinning; FDA-approved minoxidil (and oral finasteride for men) remain the proven options for pattern hair loss. On balance, Hims Hair (Finasteride + Minoxidil) edges ahead in our scoring, but the right choice depends on your situation.
Conditions these treat
Sources behind our Hims Hair (Finasteride + Minoxidil) and Vegamour GRO Hair Serum reviews
- Propecia (finasteride) Tablets — FDA Prescribing Information / Label — U.S. Food and Drug Administration (FDA) (2022)
- Finasteride Tablet, Film Coated — Prescribing Information (DailyMed Label) — DailyMed, U.S. National Library of Medicine (NIH) (2023)
- Propecia (finasteride) 1 mg — Approval Package / Medical Review — U.S. Food and Drug Administration (FDA) (2011)
- Minoxidil Topical Solution 5% — minoxidil solution (DailyMed Label) — DailyMed, U.S. National Library of Medicine (NIH) (2023)
- Minoxidil Topical Solution 2% — solution (DailyMed Label) — DailyMed, U.S. National Library of Medicine (NIH) (2023)
- Minoxidil — StatPearls (Mechanism of Action, Efficacy, Safety) — StatPearls, NCBI Bookshelf (NIH) (2024)
- Androgenetic Alopecia — StatPearls (Pathogenesis, Epidemiology, Treatment) — StatPearls, NCBI Bookshelf (NIH) (2024)
- Male Androgenetic Alopecia — Endotext — Endotext, NCBI Bookshelf (NIH) (2019)
- Long-term (5-year) Multinational Experience with Finasteride 1 mg in the Treatment of Men with Androgenetic Alopecia — European Journal of Dermatology (PubMed) (2002)
- Long-term Treatment with Finasteride 1 mg Decreases the Likelihood of Developing Further Visible Hair Loss in Men with Androgenetic Alopecia — European Journal of Dermatology (PubMed) (2008)
- Finasteride, 1 mg Daily Administration on Male Androgenetic Alopecia in Different Age Groups: 10-Year Follow-up — Dermatologic Therapy (PubMed) (2011)
- Efficacy and Safety of Topical Finasteride Spray Solution for Male Androgenetic Alopecia: A Phase III, Randomized, Controlled Clinical Trial — Journal of the European Academy of Dermatology and Venereology (PubMed) (2022)
- Safety of Low-dose Oral Minoxidil Treatment for Hair Loss: A Systematic Review and Pooled-analysis of Individual Patient Data — Journal of the American Academy of Dermatology (PubMed) (2021)
- There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: A Systematic Review with Meta-Regression Analyses — Skin Appendage Disorders (PubMed Central, NIH) (2022)
- The Effectiveness of Combination Therapies for Androgenetic Alopecia: A Systematic Review and Meta-analysis — Journal of the American Academy of Dermatology (PubMed) (2020)
- Effectiveness of Combined Oral Minoxidil and Finasteride in Male Androgenetic Alopecia: A Retrospective Service Evaluation — Skin Health and Disease (PubMed Central, NIH) (2024)
- Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis — JAMA Dermatology (PubMed Central, NIH) (2022)
- The Efficacy and Safety of 5α-Reductase Inhibitors in Androgenetic Alopecia: A Network Meta-analysis and Benefit-Risk Assessment of Finasteride and Dutasteride — Journal of the American Academy of Dermatology (PubMed) (2013)
- The Efficacy and Safety of Dutasteride Compared with Finasteride in Treating Men with Androgenetic Alopecia: A Systematic Review and Meta-analysis — Clinical Interventions in Aging (PubMed) (2019)
- Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs — Clinical, Cosmetic and Investigational Dermatology (PubMed Central, NIH) (2023)
- Topical Ketoconazole for the Treatment of Androgenetic Alopecia: A Systematic Review — Dermatologic Therapy (PubMed) (2020)
- Ketoconazole Shampoo: Effect of Long-term Use in Androgenic Alopecia — Dermatology (PubMed) (1998)
- Ketoconazole as an Adjunct to Finasteride in the Treatment of Androgenetic Alopecia in Men — Medical Hypotheses (PubMed) (2004)
- Persistent Sexual Side Effects of Finasteride for Male Pattern Hair Loss — Journal of Sexual Medicine (PubMed) (2011)
- Epidemiological Landscape of Androgenetic Alopecia in the US: An All of Us Cross-sectional Study — PLOS One (PubMed Central, NIH) (2025)
- Topical Cetirizine 1% vs Minoxidil 5% Gel in Treatment of Androgenetic Alopecia (NCT04293822) — ClinicalTrials.gov, U.S. National Library of Medicine (NIH) (2020)
- Topical Finasteride & Minoxidil Men's Rx Hair Loss Spray — Product & Clinical Information — Hims (Hims & Hers Health, Inc.) — Manufacturer (2025)
- GRO Hair Serum (official product page, ingredients & 120-day clinical claims) — Vegamour (manufacturer) (2024)
- Vegamour GRO Hair Serum — full INCI ingredient list — INCIDecoder (2024)
- An Herbal Extract Combination (Biochanin A, Acetyl tetrapeptide-3, and Ginseng Extracts) versus 3% Minoxidil Solution for the Treatment of Androgenetic Alopecia: A 24-week, Prospective, Randomized, Triple-blind, Controlled Trial — The Journal of Clinical and Aesthetic Dermatology (2020)
- Curcuma aeruginosa, a novel botanically derived 5α-reductase inhibitor in the treatment of male-pattern baldness: a multicenter, randomized, double-blind, placebo-controlled study — Journal of Dermatological Treatment (2012)
- Preparation and evaluation of hair growth promoting effect of transferosomes containing red clover extract and caffeine alone or in combination — Avicenna Journal of Phytomedicine (2024)
- Effect of caffeine and testosterone on the proliferation of human hair follicles in vitro — International Journal of Dermatology (2007)
- Differential effects of caffeine on hair shaft elongation, matrix and outer root sheath keratinocyte proliferation, and TGF-β2/IGF-1-mediated regulation of the hair cycle in male and female human hair follicles in vitro — British Journal of Dermatology (2014)
- Inhibitory effects of mung bean (Vigna radiata L.) seed and sprout extracts on melanogenesis — Food Science and Biotechnology (2016)
- Effect of Red Clover Isoflavones over Skin, Appendages, and Mucosal Status in Postmenopausal Women — Obstetrics and Gynecology International (2011)
- Evaluation of Clinical Meaningfulness of Red Clover (Trifolium pratense L.) Extract to Relieve Hot Flushes and Menopausal Symptoms in Peri- and Post-Menopausal Women: A Systematic Review and Meta-Analysis of Randomized Controlled Trials — Nutrients (2021)
- Safety assessment of a highly bioavailable curcumin-galactomannoside complex (CurQfen) in healthy volunteers, with special reference to recent hepatotoxic reports of curcumin supplements: A 90-day prospective study — Toxicology Reports (2021)
- Comparing minoxidil-finasteride mixed solution with minoxidil solution alone for male androgenetic alopecia: a systematic review and meta-analysis of randomized controlled trials — Frontiers in Medicine (2025)
- Label: MINOXIDIL TOPICAL SOLUTION, 5% — minoxidil solution (Drug Facts / clinical effectiveness) — DailyMed (U.S. National Library of Medicine) (2024)
- An Open-Label Randomized Multicenter Study Assessing the Noninferiority of a Caffeine-Based Topical Liquid 0.2% versus Minoxidil 5% Solution in Male Androgenetic Alopecia — Skin Pharmacology and Physiology (2017)
- Cyclodextrin-Assisted Extraction Method as a Green Alternative to Increase the Isoflavone Yield from Trifolium pratense L. Extract — Molecules (2021)
- Curcumin, an active component of turmeric: biological activities, nutritional aspects, immunological, bioavailability, and human health benefits — a comprehensive review — Frontiers in Immunology (2025)
Editorial comparison, not medical advice. Discuss options with a qualified clinician. Individual results vary.